IDT Australia (IDT.AX) Stock Price

IDT Australia Price

ASX·CLOSED
0.04AUD-0.0010 (-2.35 %)
Market closed

Revenue at IDT Australia has contracted by 1.2% per year over the past 19 years to 19.86 M AUD. Earnings per share have declined at 13.8% per year over the last 15 years. For IDT Australia, the net margin of -40.6% is down versus 12.4% a few years ago. At today's price the dividend yield works out to roughly 34.01%. The stock trades about 35% above its 52-week low.

IDT Australia stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of IDT Australia over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how IDT Australia stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing IDT Australia's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

IDT Australia Stock Price History
DateIDT Australia Price
8/5/20260.04 AUD
8/4/20260.04 AUD
8/3/20260.04 AUD
7/31/20260.04 AUD
7/30/20260.04 AUD
7/29/20260.04 AUD
7/28/20260.03 AUD
7/27/20260.04 AUD
7/24/20260.03 AUD
7/23/20260.03 AUD
7/22/20260.03 AUD
7/21/20260.04 AUD
7/20/20260.03 AUD
7/17/20260.03 AUD
7/16/20260.03 AUD
7/15/20260.03 AUD
7/14/20260.03 AUD
7/13/20260.03 AUD
7/10/20260.03 AUD
7/9/20260.03 AUD
7/8/20260.03 AUD
7/7/20260.03 AUD
7/6/20260.03 AUD
7/3/20260.03 AUD
7/2/20260.03 AUD
7/1/20260.03 AUD
6/30/20260.03 AUD
6/29/20260.03 AUD
6/26/20260.03 AUD
6/25/20260.03 AUD
6/24/20260.03 AUD
6/23/20260.03 AUD
6/22/20260.03 AUD
6/19/20260.03 AUD
6/18/20260.03 AUD
6/17/20260.04 AUD
6/16/20260.03 AUD
6/15/20260.03 AUD
6/12/20260.03 AUD
6/11/20260.03 AUD
6/10/20260.03 AUD
6/9/20260.04 AUD
6/5/20260.04 AUD
6/4/20260.04 AUD
6/3/20260.04 AUD
6/2/20260.04 AUD
6/1/20260.04 AUD
5/29/20260.04 AUD
5/28/20260.04 AUD
5/27/20260.04 AUD
5/26/20260.04 AUD
5/25/20260.04 AUD
5/22/20260.03 AUD
5/21/20260.04 AUD
5/20/20260.04 AUD
5/19/20260.04 AUD
5/18/20260.04 AUD
5/15/20260.04 AUD
5/14/20260.04 AUD
5/13/20260.04 AUD
5/12/20260.04 AUD
5/11/20260.04 AUD
5/8/20260.04 AUD
5/7/20260.04 AUD
5/6/20260.04 AUD
5/5/20260.04 AUD
5/4/20260.04 AUD
5/1/20260.04 AUD
4/30/20260.04 AUD
4/29/20260.04 AUD
4/28/20260.04 AUD
4/27/20260.04 AUD
4/24/20260.04 AUD
4/23/20260.04 AUD
4/22/20260.04 AUD
4/21/20260.04 AUD
4/20/20260.04 AUD
4/17/20260.04 AUD
4/16/20260.04 AUD
4/15/20260.04 AUD
4/14/20260.04 AUD
4/13/20260.04 AUD
4/10/20260.05 AUD
4/9/20260.05 AUD
4/8/20260.05 AUD
4/7/20260.04 AUD
4/2/20260.04 AUD
4/1/20260.04 AUD
3/31/20260.04 AUD
3/30/20260.04 AUD
3/27/20260.04 AUD
3/26/20260.04 AUD
3/25/20260.05 AUD
3/24/20260.05 AUD
3/23/20260.04 AUD
3/20/20260.04 AUD
3/19/20260.04 AUD
3/18/20260.04 AUD
3/17/20260.04 AUD
3/16/20260.04 AUD
3/13/20260.04 AUD
3/12/20260.04 AUD
3/11/20260.05 AUD
3/10/20260.05 AUD
3/9/20260.05 AUD
3/6/20260.05 AUD
3/5/20260.05 AUD
3/4/20260.05 AUD
3/3/20260.05 AUD
3/2/20260.05 AUD
2/27/20260.05 AUD
2/26/20260.05 AUD
2/25/20260.05 AUD
2/24/20260.05 AUD
2/23/20260.05 AUD
2/20/20260.05 AUD
2/19/20260.05 AUD
2/18/20260.05 AUD
2/17/20260.04 AUD
2/16/20260.05 AUD
2/13/20260.05 AUD
2/12/20260.05 AUD
2/11/20260.05 AUD
2/10/20260.05 AUD
2/9/20260.05 AUD
2/6/20260.05 AUD
2/5/20260.05 AUD
2/4/20260.05 AUD
2/3/20260.05 AUD
2/2/20260.05 AUD
1/30/20260.05 AUD
1/29/20260.05 AUD
1/28/20260.05 AUD
1/27/20260.05 AUD
1/23/20260.05 AUD
1/22/20260.05 AUD
1/21/20260.05 AUD
1/20/20260.05 AUD
1/19/20260.05 AUD
1/16/20260.05 AUD
1/15/20260.05 AUD
1/14/20260.05 AUD
1/13/20260.05 AUD
1/12/20260.05 AUD
1/9/20260.05 AUD
1/8/20260.05 AUD
1/7/20260.05 AUD
1/6/20260.05 AUD
1/5/20260.05 AUD
1/2/20260.05 AUD
12/31/20250.05 AUD
12/30/20250.05 AUD
12/29/20250.05 AUD
12/24/20250.05 AUD
12/23/20250.05 AUD
12/22/20250.05 AUD
12/19/20250.05 AUD
12/18/20250.06 AUD
12/17/20250.06 AUD
12/16/20250.06 AUD
12/15/20250.05 AUD
12/12/20250.05 AUD
12/11/20250.06 AUD
12/10/20250.06 AUD
12/9/20250.05 AUD
12/8/20250.05 AUD
12/5/20250.05 AUD
12/4/20250.05 AUD
12/3/20250.05 AUD
12/2/20250.05 AUD
12/1/20250.05 AUD
11/28/20250.05 AUD
11/27/20250.05 AUD
11/26/20250.05 AUD
11/25/20250.06 AUD
11/24/20250.06 AUD
11/21/20250.06 AUD
11/20/20250.06 AUD
11/19/20250.06 AUD
11/18/20250.06 AUD
11/17/20250.06 AUD
11/14/20250.06 AUD
11/13/20250.06 AUD
11/12/20250.06 AUD
11/11/20250.06 AUD
11/10/20250.06 AUD
11/7/20250.06 AUD
11/6/20250.06 AUD
11/5/20250.06 AUD
11/4/20250.06 AUD
11/3/20250.06 AUD
10/31/20250.06 AUD
10/30/20250.06 AUD
10/29/20250.06 AUD
10/28/20250.06 AUD
10/27/20250.06 AUD
10/24/20250.06 AUD
10/23/20250.06 AUD
10/22/20250.06 AUD
10/21/20250.06 AUD
10/20/20250.06 AUD
10/17/20250.06 AUD
10/16/20250.06 AUD
10/15/20250.06 AUD
10/14/20250.06 AUD
10/13/20250.06 AUD
10/10/20250.06 AUD
10/9/20250.06 AUD
10/8/20250.06 AUD
10/7/20250.06 AUD
10/6/20250.06 AUD
10/3/20250.06 AUD
10/2/20250.06 AUD
10/1/20250.06 AUD
9/30/20250.06 AUD
9/29/20250.06 AUD
9/26/20250.06 AUD
9/25/20250.06 AUD
9/24/20250.06 AUD
9/23/20250.06 AUD
9/22/20250.06 AUD
9/19/20250.06 AUD
9/18/20250.06 AUD
9/17/20250.06 AUD
9/16/20250.06 AUD
9/15/20250.06 AUD
9/12/20250.06 AUD
9/11/20250.06 AUD
9/10/20250.06 AUD
9/9/20250.06 AUD
9/8/20250.06 AUD
9/5/20250.07 AUD
9/4/20250.06 AUD
9/3/20250.07 AUD
9/2/20250.06 AUD
9/1/20250.06 AUD
8/29/20250.07 AUD
8/28/20250.06 AUD
8/27/20250.07 AUD
8/26/20250.07 AUD
8/25/20250.07 AUD
8/22/20250.07 AUD
8/21/20250.07 AUD
8/20/20250.07 AUD
8/19/20250.07 AUD
8/18/20250.07 AUD
8/15/20250.07 AUD
8/14/20250.07 AUD
8/13/20250.07 AUD
8/12/20250.07 AUD
8/11/20250.07 AUD
8/8/20250.07 AUD
Access this data via the Eulerpool API
Get Free API Key

IDT Australia Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
14.17 M AUD
-1.25 M AUD
-1.92 M AUD
Jan 1, 2021
16.93 M AUD
966,000.00 AUD
2.10 M AUD
Jan 1, 2022
12.13 M AUD
-1.88 M AUD
-1.16 M AUD
Jan 1, 2023
7.03 M AUD
-9.78 M AUD
-8.50 M AUD
Jan 1, 2024
14.12 M AUD
-5.96 M AUD
-5.41 M AUD
Jan 1, 2025
19.86 M AUD
-7.30 M AUD
-8.06 M AUD
Jan 1, 2026 (e)
27.40 M AUD
-10.74 M AUD
2.99 M AUD
Jan 1, 2027 (e)
32.00 M AUD
-12.54 M AUD
5.98 M AUD

IDT Australia Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 8:22 PM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
DIV.AUD
DIV. GROWTH%
SHARESM
201220132014201520162017201820192020202120222023202420252026e2027e
9.0010.0013.0015.007.009.0013.0012.0014.0016.0012.007.0014.0019.0027.0032.00
-30.7711.1130.0015.38-53.3328.5744.44-7.6916.6714.29-25.00-41.67100.0035.7142.1118.52
100.00100.0076.9293.3385.7177.7876.9275.0085.7193.7583.3357.1478.5768.4268.4268.42
9.0010.0010.0014.006.007.0010.009.0012.0015.0010.004.0011.0013.0018.4721.89
-2.00-4.00-5.00-3.00-5.00-7.00-4.00-5.00-1.00–-1.00-9.00-5.00-7.00-10.00-12.00
-22.22-40.00-38.46-20.00-71.43-77.78-30.77-41.67-7.14–-8.33-128.57-35.71-36.84-37.04-37.50
-1.00-5.00-6.00-2.00-4.00–-16.00-6.00-1.002.00-1.00-8.00-5.00-8.002.005.00
–400.0020.00-66.67100.00––-62.50-83.33-300.00-150.00700.00-37.5060.00-125.00150.00
––––––––––––––0.080.08
––––––––––––––––
45.5947.1069.60137.70208.17247.61247.83239.46237.12245.71246.59250.57349.23427.38427.38427.38
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales IDT Australia generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue IDT Australia retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare IDT Australia's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares IDT Australia has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against IDT Australia's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

IDT Australia stock margins

The IDT Australia margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IDT Australia. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IDT Australia.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
88.64 %
-8.79 %
-13.54 %
Jan 1, 2021
88.94 %
5.71 %
12.42 %
Jan 1, 2022
88.13 %
-15.47 %
-9.56 %
Jan 1, 2023
68.98 %
-139.02 %
-120.85 %
Jan 1, 2024
80.11 %
-42.18 %
-38.33 %
Jan 1, 2025
69.19 %
-36.78 %
-40.60 %
Jan 1, 2026 (e)
69.19 %
-39.19 %
10.92 %
Jan 1, 2027 (e)
69.19 %
-39.19 %
18.70 %

IDT Australia Stock Revenue, EBIT, Earnings per Share

The IDT Australia earnings per share therefore indicates how much revenue IDT Australia has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.06 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2021
0.07 AUD
0.00 AUD
0.01 AUD
Jan 1, 2022
0.05 AUD
-0.01 AUD
-0.00 AUD
Jan 1, 2023
0.03 AUD
-0.04 AUD
-0.03 AUD
Jan 1, 2024
0.04 AUD
-0.02 AUD
-0.02 AUD
Jan 1, 2025
0.05 AUD
-0.02 AUD
-0.02 AUD
Jan 1, 2026 (e)
0.06 AUD
-0.03 AUD
0.01 AUD
Jan 1, 2027 (e)
0.07 AUD
-0.03 AUD
0.01 AUD

IDT Australia business model & stock analysis

IDT Australia Ltd is a leading company in the development and manufacturing of pharmaceutical active ingredients and other biological products. The company was founded in 1974 and is headquartered in Melbourne, Australia. For over 40 years, IDT has been working to develop innovative solutions and products to improve the health and well-being of people worldwide. The history of IDT Australia Ltd began with the goal of Walter and Elke Kortschak to establish a company that produces high-quality pharmaceutical active ingredients. The company started its active ingredient production in a small facility in Melbourne and was able to grow quickly. In the following years, IDT expanded into various areas of the pharmaceutical industry and is now a leading manufacturer of drugs, vaccines, and diagnostics. IDT Australia Ltd is divided into four main areas: active ingredients, biologics, diagnostics, and vaccines. Each of these areas has unique products and services offered by the company. In the field of active ingredients, IDT Australia Ltd offers a wide range of pharmaceutical active ingredients. The company specializes in the production of API's (Active Pharmaceutical Ingredients) used in the manufacturing of drugs. The product range includes strong painkillers to cancer drugs. IDT also produces custom active ingredients tailored to the specific needs of a customer. In the field of biologics, IDT Australia Ltd specializes in the production of biological products. Here, the company offers an extensive range of products such as antibodies, enzymes, recombinant proteins, and more. These products are used in drug research and development and in diagnostics. The diagnostics sector includes both diagnostic tests and test kits. IDT produces tests for a variety of conditions such as hypertension, diabetes, metabolic disorders, and infectious diseases. The diagnostics division of IDT has become an important part of the company, supporting accurate diagnosis, rapid decision-making, and optimal treatment of diseases. The vaccines sector is one of the newest areas at IDT Australia Ltd. In this field, the company specializes in the production of vaccines against infectious diseases. This means that IDT is one of the few Australian companies with the capability to develop and produce vaccines. The company works closely with the Australian government, private health organizations, and other companies to ensure the development of effective vaccines against serious infectious diseases. IDT Australia Ltd takes pride in offering products and services of the highest quality. The company is committed to meeting the requirements and expectations of its customers—and beyond. From the development of new medications to the production of high-quality active ingredients, biologics, diagnostics, and vaccines, IDT carefully monitors all production processes. The company continually invests in research and development to improve processes and products. The work of IDT Australia Ltd has received countless awards and recognition, both in Australia and internationally. The company is among the ten Australian companies represented in the Global Cleantech 100 in 2017. IDT Australia Ltd also holds the record for the fastest order processing for a medical device in Australia. However, the success of the company is not only measured by its industry and customer recognition, but also by the commitment of its employees to research, innovation, and improved health worldwide. Overall, IDT Australia Ltd plays a significant role in the development and manufacturing of active ingredients, biologics, diagnostics, and vaccines. The products and services of the company have the potential to improve the lives of millions of people worldwide. IDT Australia Ltd is on track to continue being a driving force in the development and production of new products in the pharmaceutical industry.

IDT Australia SWOT Analysis

Strengths

IDT Australia Ltd possesses several key strengths that contribute to its success in the market. First and foremost, the company has a strong and experienced management team that brings valuable expertise to the table. This allows them to make strategic decisions effectively and navigate the industry with confidence. Additionally, IDT Australia Ltd has a diverse product portfolio that includes innovative pharmaceuticals and biotechnology products. This enables the company to cater to a wide range of customer needs and stay ahead of competitors.

Weaknesses

Despite its strengths, IDT Australia Ltd also faces certain weaknesses that need to be addressed. One notable weakness is the company's heavy reliance on a limited number of suppliers for raw materials. This puts IDT at risk of potential supply chain disruptions, which may impact production and timely delivery of products. Another weakness is the company's relatively small market share compared to some larger competitors, which limits its bargaining power and hinders expansion opportunities.

Opportunities

IDT Australia Ltd operates in an industry that presents several growth opportunities. The increasing global demand for pharmaceutical products and biotechnology advancements provides a favorable market for the company to expand its customer base and increase sales. Moreover, the growing importance of research and development in the healthcare sector opens doors for IDT to invest in innovation and develop new, groundbreaking products. Additionally, the company can explore strategic partnerships and collaborations to leverage the expertise and resources of other organizations.

Threats

IDT Australia Ltd faces certain threats that may pose challenges to its growth and profitability. One significant threat is intense competition from both domestic and international pharmaceutical companies. This requires IDT to continually differentiate itself through product quality, pricing, and marketing strategies to maintain its market position. Another threat is the stringent regulatory environment governing the healthcare industry, which can lead to increased compliance costs and delays in product approvals.

IDT Australia Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

IDT Australia historical P/E ratio, EBIT multiple, and P/S ratio

IDT Australia annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

IDT Australia shares outstanding

The number of shares of IDT Australia was 427.38 M in 2025. This indicates how many shares IDT Australia is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
237.12 M Stocks
Jan 1, 2021
245.71 M Stocks
Jan 1, 2022
246.59 M Stocks
Jan 1, 2023
250.57 M Stocks
Jan 1, 2024
349.23 M Stocks
Jan 1, 2025
427.38 M Stocks
Jan 1, 2026 (e)
427.38 M Stocks
Jan 1, 2027 (e)
427.38 M Stocks

IDT Australia stock splits

In IDT Australia's history, there have been no stock splits.

IDT Australia Dividend History

20 years of dividend payments

YearAnnual DividendYoY ChangePayments
20100.01AUD↓ 90.5%1×
20090.15AUD↓ 12.5%2×
20080.17AUD↑ 20.0%2×
20070.14AUD↑ 25.0%2×
20060.11AUD 0.0%2×
20050.11AUD↑ 14.3%2×
20040.10AUD↑ 16.7%2×
20030.09AUD↑ 20.0%2×
20020.07AUD↑ 21.7%2×
20010.06AUD↓ 20.8%2×

IDT Australia dividend payout ratio

In 2025, IDT Australia had a payout ratio of 103.38%. The payout ratio indicates the percentage of the company's profits that IDT Australia distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
103.39 %
Jan 1, 2021
103.37 %
Jan 1, 2022
103.38 %
Jan 1, 2023
103.38 %
Jan 1, 2024
103.37 %
Jan 1, 2025
103.38 %
Jan 1, 2026 (e)
1,159.96 %
Jan 1, 2027 (e)
579.98 %
Price targets and forecasts for IDT Australia are not yet available.

IDT Australia shareholder structure

% Name
0.32763%
Sam (Geoffrey Joseph)
Sam (Geoffrey Joseph)
0.25455%
Simari (Mark Anthony)
Simari (Mark Anthony)
0.00000%
Schröder Equities GmbH
Schröder Equities GmbH

IDT Australia Beneficial Ownership Filings (SEC 13D/G)

Free Float
81.3%
Float Shares
-
Shares Outstanding
-

IDT Australia Executives and Management Board

8 members · avg. age 59 · 13 % women

PM

Mr. Paul Mcdonald

Chief Executive Officer

321,786.00 AUD

Management

CK

Mr. Chris Kagiaros

Head of People and Culture

246,924.00 AUD
MV

Mr. Mahendran Vasanthakumar

Interim Chief Financial Officer

–
ML

Mr. Mark Licciardo

Company Secretary

–

Board of Directors

HB

Mr. Hugh Burrill (61)

Non-Executive Independent Director

70,000.00 AUD
JR

Dr. Jane Ryan

Non-Executive Independent Director

29,722.00 AUD
MS

Mr. Mark Simari (51)

Non-Executive Independent Chairman of the Board

–
GS

Mr. Geoffrey Sam (66)

Independent Non-Executive Director

–

IDT Australia Supply Chain

IDT Australia Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#NameTrend
1
Citigroup
Supplier·Customer·Banks·US
0.09
-0.25
0.73
0.56
0.68
0.67
2
UBS Group
Supplier·Customer·Capital Markets·CH
0.39
0.48
-0.07
-0.14
-0.43
0.32
#NameTrend
1
HSBC Holdings
Supplier·Customer·Banks·GB
0.61
-0.15
0
-0.64
-0.82
-0.01

Frequently asked questions about IDT Australia

IDT Australia Ltd operates as a pharmaceutical manufacturing and distribution company. The company's business model focuses on developing, manufacturing, and marketing a diverse range of pharmaceutical products. IDT Australia Ltd specializes in research-based, innovative medicines and aims to provide high-quality and cost-effective healthcare solutions. With its state-of-the-art manufacturing facilities, the company offers contract manufacturing services to various global pharmaceutical companies. IDT Australia Ltd's business model revolves around delivering safe, efficacious, and reliable pharmaceuticals, ensuring the highest standards of quality and compliance. The company strives to be a trusted partner for pharmaceutical development and production, catering to the evolving needs of the healthcare industry.

IDT Australia Ltd is primarily active in the pharmaceutical industry.

The main competitors of IDT Australia Ltd in the market include pharmaceutical companies like Mayne Pharma Group Limited, Sigma Healthcare Limited, and Australian Pharmaceutical Industries Limited. These companies are also involved in the manufacturing and distribution of pharmaceutical products, making them direct competitors to IDT Australia Ltd.

IDT Australia Ltd is an Australian pharmaceutical company with a rich history and background. Established in 1975, IDT Australia has evolved into a prominent player in the pharmaceutical industry. The company specializes in the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs), finished dose pharmaceuticals, and consumer healthcare products. With its state-of-the-art facilities and dedicated team of experts, IDT Australia has gained a reputation for delivering high-quality and innovative solutions. The company focuses on providing contract manufacturing and development services to both domestic and international customers. IDT Australia's commitment to excellence and its strong presence in the market make it a trusted name in the pharmaceutical sector.

IDT Australia Ltd has achieved several significant milestones in its history. One notable milestone is the acquisition of the HealthPro brand in 2010, which expanded their presence in the global pharmaceutical market. Additionally, the company received its Therapeutic Goods Administration (TGA) license in 2012, allowing them to manufacture and supply quality pharmaceutical products. Moreover, IDT Australia Ltd successfully obtained the Schedule 8 license in 2017, enabling them to manufacture and supply controlled substances. These milestones illustrate the company's commitment to growth and its ability to navigate regulatory requirements. IDT Australia Ltd continues to strive for excellence in the pharmaceutical industry.

IDT Australia Ltd is primarily present in Australia and New Zealand.

IDT Australia Ltd represents a strong commitment to innovation, quality, and customer satisfaction. The company values include integrity, transparency, and a focus on long-term sustainable growth. IDT Australia Ltd is dedicated to providing high-quality solutions and services in the pharmaceutical industry. Their corporate philosophy emphasizes collaboration, efficiency, and continuous improvement. With a dedicated team of professionals, IDT Australia Ltd aims to deliver value to its stakeholders through responsible and ethical practices. Overall, IDT Australia Ltd strives to be a trusted and reliable partner, offering cutting-edge solutions and contributing to the advancement of healthcare globally.

7 analysts currently rate the IDT Australia stock: 0 recommend buying, 3 holding and 4 selling. For 2026, analysts expect IDT Australia to generate revenue of 27.40 M AUD and earnings per share of 0.01 AUD.

IDT Australia Analyst Price Targets 2026

Converted at the current exchange rate, the IDT Australia share trades at 0.03 EUR (0.04 AUD).

The IDT Australia share (IDT.AX) is listed on 1 stock exchanges, including: ASX (IDT.AX).

IDT Australia Ltd is a leading company in the production and distribution of high-quality pharmaceutical products, particularly in the development and production of high-quality active ingredients and intermediates for the synthesis of drugs. The company also offers its expertise in research and development as well as sales and marketing. The company is divided into several business areas, including the production of APIs (Active Pharmaceutical Ingredients), intermediates, and fine chemicals. The company is also involved in the development of synthesis routes and process development. IDT Australia Ltd has extensive expertise in the production of active ingredients and pharmaceuticals. The company's products are used in various areas such as human and veterinary medicine, agrochemistry, and the chemical industry. The APIs division includes a wide range of products, including analgesics, cardiology, antihypertensives, anti-infectives, antidiabetics, rheumatology, and dermatology. The company has expanded its product range to include new and innovative products to meet the increasing demand of its customers. IDT Australia Ltd prides itself on offering its customers high-quality products that meet the strict regulations of the FDA and international standards. The intermediates division is also important to the company's business model. IDT Australia Ltd produces intermediates for a variety of drug classes, including cancer drugs, infectious diseases, autoimmune diseases, and metabolic disorders. The company is able to provide its customers with tailor-made intermediates to meet their requirements and specific needs. Another important aspect of IDT Australia Ltd's business model is research and development. The company has extensive expertise and experience in the synthesis of active ingredients and pharmaceuticals. IDT Australia Ltd invests continuously in research and development to be able to offer its customers innovative products. The company is proud to be able to provide its customers with customized solutions and assistance in the implementation of development processes. In the area of sales and marketing, IDT Australia Ltd works closely with its customers from the pharmaceutical and chemical industries to offer them a wide range of services. The company provides its customers with technical support in the implementation of development processes and in the analysis of quality issues, as well as an efficient supply chain. In summary, IDT Australia Ltd is a renowned company specializing in the production of active ingredients and pharmaceuticals, intermediates, and fine chemicals. The company takes pride in offering its customers a wide range of products and utilizing the experience and expertise of its employees in the areas of research and development, process development, sales, and marketing. With its quality products and comprehensive services, IDT Australia Ltd is able to meet the needs of its customers and be a reliable partner in a competitive market.

The expected revenue of IDT Australia is 27.40 M AUD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of IDT Australia is 2.99 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of IDT Australia is currently 6.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IDT Australia stock.

The price-to-sales ratio (P/S) of IDT Australia is currently 0.66. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IDT Australia stock.

The Eulerpool Quality Score for IDT Australia is 2/10.

The ISIN of IDT Australia is AU000000IDT0. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of IDT Australia is 502203. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of IDT Australia is IDT.AX. The ticker symbol is used to trade IDT Australia shares on the stock exchange.

Over the past 12 months, IDT Australia paid a dividend of 0.01 AUD . This corresponds to a dividend yield of about 34.01 %. For the coming 12 months, IDT Australia is expected to pay a dividend of 0.08 AUD.

The current dividend yield of IDT Australia is 34.01 %.

IDT Australia pays a dividend, distributed in the months of , , , .

IDT Australia paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0.08 AUD are expected. This corresponds to a dividend yield of 193.33 %.

IDT Australia is assigned to the 'Health' sector.

To receive the latest dividend of IDT Australia from amounting to 0.01 AUD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of IDT Australia are distributed in AUD.

All fundamentals and in-depth analysis of IDT Australia

Our stock analysis for IDT Australia stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IDT Australia. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

IDT Australia Stock
IDT Australia Revenue→
IDT Australia Stock
IDT Australia Net Income→
IDT Australia Stock
IDT Australia P/E→
IDT Australia Stock
IDT Australia P/S→
IDT Australia Stock
IDT Australia EBIT→
IDT Australia Stock
IDT Australia Dividend→
IDT Australia Stock
IDT Australia Directors Dealings→
IDT Australia Stock
IDT Australia Stocks→
IDT Australia Stock
IDT Australia Market capitalization→
IDT Australia Stock
IDT Australia Debt→
IDT Australia Stock
IDT Australia Liabilities→
IDT Australia Stock
IDT Australia Equity→
IDT Australia Stock
IDT Australia AAQS→
IDT Australia Stock
IDT Australia Employees→
IDT Australia Stock
IDT Australia ROE→
IDT Australia Stock
IDT Australia ROA→
IDT Australia Stock
IDT Australia ROCE→
IDT Australia Stock
IDT Australia News→
IDT Australia Stock
IDT Australia Analyst Price Targets→

Health Stocks

Ifa SystemsIdorsiaIkonisysIDL Diagnostics AB (publ)Il Dong Pharmaceutical CoIDEXX LaboratoriesIldong Holdings CoIDEAYA BiosciencesIlex MedicalICU MedicalIlluminaIconovoAll Stocks A–Z →